<< InfoSite Home
Starting Your Patients on NAMENDA
Easy dosing and administration2
Recommended maintenance dose is 10 mg BID after titration
- The recommended maintenance dose is reached by day 22 of therapy (just 3 weeks after the start of treatment)
- Can be administered with or without food
- In patients with severe renal impairment, the dosage should be reduced
NAMENDA is offered in a convenient Titration Pak for the first 4 weeks of therapy
Preferred status on the majority of health plan and Medicare Part D formularies4
- A unique MOA puts NAMENDA in a class of its own, as categorized by
USP Guidelines†5
Easy to start with…
- NAMENDA is available in:
- Retail pharmacies by prescription as the NAMENDA Titration Pak
- Physicians' offices as a Patient Starter Kit sample
Easy to stay with…
- Maintenance prescription
NAMENDA oral solution
- Ideally suited for patients who prefer taking a liquid or have difficulty swallowing tablets
- Contains 2 mg of active medication per mL
(2.5 mL=5 mg;
5 mL=10 mg)
†Under the Medicare Prescription Drug, Improvement, and Modernization Act (MMA), the United States Pharmacopeia (USP) developed Model Guidelines Version 2.0, outlining drug categories and classes that may be used by prescription drug plans in developing their formularies. The USP Guidelines were used as the classification structure for approximately 74% of formularies that were in place when the new Medicare Part D benefit became activated January 1, 2006.7,8
Important Safety Information
NAMENDA® (memantine HCl) is indicated for the treatment of moderate to severe Alzheimer's disease. NAMENDA has been used by more than 2 million people worldwide.NAMENDA is contraindicated in patients with known hypersensitivity to memantine HCl or any excipients used in the formulation. The most common adverse events reported with NAMENDA vs placebo (≥5% and higher than placebo) were dizziness, confusion, headache, and constipation. In patients with severe renal impairment, the dosage should be reduced.
See Full Prescribing Information